NCI Funds Range of Prostate Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 5
Volume 8
Issue 5

BETHESDA, Md-The National Cancer Institute is funding a wide range of prostate cancer research, including genetic epidemiology, molecular diagnostics, diet and nutrition, animal models, surveillance, diagnostic imaging, clinical trials, prevention and early detection, and the Cancer Genome Anatomy Project .

BETHESDA, Md—The National Cancer Institute is funding a wide range of prostate cancer research, including genetic epidemiology, molecular diagnostics, diet and nutrition, animal models, surveillance, diagnostic imaging, clinical trials, prevention and early detection, and the Cancer Genome Anatomy Project .

For a list of grant opportunities and contacts, visit the NCI’s website at www.nci.nih.gov/prostate.html.

Articles in this issue
Delirium Is Often Misdiagnosed in Advanced Cancer
Preop Chemo Recommended for Locally Advanced Disease
High Degree of Variability in HIV Testing Throughout the US
Physicians Need ‘Coherent Game Plan’ for Care of Dying
NCI Funds Pediatric Brain Tumor Consortium
Marketing Your Cancer Center to Today’s Savvy Consumers
Axillary Irradiation Can Replace Dissection in Some Breast Cancer’s
Dr. Bailes Urges Oncologists to Act Against APC Proposal
Elective Lymph Node Dissection Supported in Some Melanomas
Broad Coalition of Health Care Groups Opposes APCs
Depression and Anxiety Difficult to Diagnose in Cancer Patients
Tips on Distinguishing Good Metaanalyses From Poor Ones
How Patients Hear a Cancer Diagnosis Can Affect Long-Term QOL
Neoadjuvant Hormonal Therapy in Prostate Cancer: Pro and Con
Treating Patients on Protocol More Effective, No More Costly
Recent Videos
4 experts in this video
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Multidisciplinary collaboration may help in minimizing the treatment burden among patients with prostate cancer, according to Curtiland Deville Jr., MD.
4 experts in this video
Related Content
Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC

Landmark Radioligand Therapy Approval Bridges Treatment Gap in mCRPC

Ariana Pelosci
April 18th 2025
Article

Administering 177Lu for mCRPC is a “team sport”, according to Steven Finkelstein, MD, DABR, FACRO.

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Navigating Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;David Morris, MD, MS;Tanya B. Dorff, MD;Mark T. Fleming, MD
March 5th 2025
Podcast

A patient case of a 50-year-old man with hormone-sensitive prostate cancer sparked a debate among oncologists regarding the best course of action.

Pembrolizumab/Docetaxel Does Not Improve OS/rPFS Outcomes in mCRPC

Pembrolizumab/Docetaxel Does Not Improve OS/rPFS Outcomes in mCRPC

Tim Cortese
April 15th 2025
Article

Results from the KEYNOTE-921 trial demonstrated that pembrolizumab with docetaxel did not elicit efficacy improvements vs placebo with docetaxel in prostate cancer.

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Leveraging Artificial Intelligence Evolutions in Prostate Cancer Care

James B. Yu, MD, MHS, FASTRO;Julian C. Hong, MD, MS
July 1st 2024
Podcast

AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

FDA Approves Radioligand Therapy in PSMA–Positive, Castration-Resistant PC

Tim Cortese
March 28th 2025
Article

Results from PSMAfore show that lutetium Lu 177 vipivotide tetraxetan elicited a median rPFS of 9.3 months vs 5.6 months with ARPI in prostate cancer.

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Post-Radical Prostatectomy PSA Levels Reduced Overtreatment Risk After 3 Months

Tim Cortese
March 26th 2025
Article

A cohort study found that pre-radical prostatectomy levels greater than 20 ng/mL were associated with increased all-cause mortality risk and prostate cancer-specific mortality risk.